Overview

A Study of TY-302 in Patients With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of TY-302 single and the combination with Tamoxifen in dose-escalation and dose-expansion study.The drugs involved in this study are: - TY-302 - Tamoxifen
Phase:
Phase 1
Details
Lead Sponsor:
TYK Medicines, Inc
Treatments:
Tamoxifen